When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
REPL - Replimune: The Fall Is Justified As Virus Therapy Fails Again In Cancer
Replimune Group Inc.
2024-01-23 13:22:24 ET
Summary
Replimune Group is developing virus-based treatments for solid tumors, particularly skin cancer.
The company's RP1 treatment did not show significant improvement in response rates compared to standard care in a phase 1/2 study, though there is a signal of something buried therein.
Replimune plans to initiate a confirmatory study for RP1 in melanoma patients and is also developing RP2 for uveal melanoma.